{"created":"2023-06-19T07:25:41.967681+00:00","id":13726,"links":{},"metadata":{"_buckets":{"deposit":"0f7f97c6-0b4b-42f4-9a7d-2c48a1749362"},"_deposit":{"created_by":79,"id":"13726","owners":[79],"pid":{"revision_id":0,"type":"depid","value":"13726"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00013726","sets":["212:260:312"]},"author_link":["29173","29175","29169","29171","29174","29170","29172"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"9","bibliographicPageEnd":"544","bibliographicPageStart":"528","bibliographicVolumeNumber":"45","bibliographic_titles":[{"bibliographic_title":"医療薬学"}]}]},"item_3_textarea_2":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_textarea_value":"\tWhen anticancer drugs that are eliminated through the kidney are administered to patients with renal failure, their dosage should be reduced according to renal function to avoid severe side effects associated with delays in elimination. We have established dose reduction criteria for cisplatin, capecitabine, and gimeracil/tegaful/oteracil potassium administered to patients with renal failure, aiming to develop a common viewpoint among the medical staff. The dose reduction criteria were utilized to select the chemotherapy regimens in a conference and to check prescriptions in the pharmacy. After establishing the dose reduction criteria, improper dose and/or regimen administered patients with renal failure were decreased significantly. This suggested that establishment of dose reduction criteria contributed to the proper use of anticancer drugs eliminated through the kidney in patients with renal failure. However, it is necessary to accumulate clinical evidence evaluating whether dose reduction results in reduced therapeutic effects"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"*Cisplatin(薬理学,毒性・副作用,治療的利用)","subitem_subject_scheme":"Other"},{"subitem_subject":"胃腫瘍(薬物療法)","subitem_subject_scheme":"Other"},{"subitem_subject":"薬剤処方","subitem_subject_scheme":"Other"},{"subitem_subject":"大腸腫瘍(薬物療法)","subitem_subject_scheme":"Other"},{"subitem_subject":"胆道腫瘍(薬物療法)","subitem_subject_scheme":"Other"},{"subitem_subject":"投薬計画","subitem_subject_scheme":"Other"},{"subitem_subject":"アジュバント化学療法","subitem_subject_scheme":"Other"},{"subitem_subject":"後向き研究","subitem_subject_scheme":"Other"},{"subitem_subject":"治療成績","subitem_subject_scheme":"Other"},{"subitem_subject":"*Capecitabine(薬理学,毒性・副作用,治療的利用)","subitem_subject_scheme":"Other"},{"subitem_subject":"*TS-1(薬理学,毒性・副作用,治療的利用)","subitem_subject_scheme":"Other"},{"subitem_subject":"*医薬品適正使用","subitem_subject_scheme":"Other"},{"subitem_subject":"腎機能障害","subitem_subject_scheme":"Other"},{"subitem_subject":"*腎排出","subitem_subject_scheme":"Other"},{"subitem_subject":"処方監査","subitem_subject_scheme":"Other"},{"subitem_subject":"ヒト","subitem_subject_scheme":"Other"},{"subitem_subject":"中年(45〜64)","subitem_subject_scheme":"Other"},{"subitem_subject":"高齢者(65〜79)","subitem_subject_scheme":"Other"},{"subitem_subject":"男","subitem_subject_scheme":"Other"},{"subitem_subject":"女","subitem_subject_scheme":"Other"},{"subitem_subject":"patient with renal failure","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"anticancer drug eliminated through the kidney","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"dose reduction criteria","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"gimeracil/tegaful/oteracil potassium (S-1)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"adjuvant chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"院内統一基準の作成による腎排泄型抗がん剤の適正使用に関する検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"院内統一基準の作成による腎排泄型抗がん剤の適正使用に関する検討"},{"subitem_title":"Survey of proper use of anticancer drugs eliminated through the kidney due to establishment of uniform dose reduction criteria in the institution","subitem_title_language":"en"}]},"item_type_id":"3","owner":"79","path":["312"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-03-04"},"publish_date":"2020-03-04","publish_status":"0","recid":"13726","relation_version_is_last":true,"title":["院内統一基準の作成による腎排泄型抗がん剤の適正使用に関する検討"],"weko_creator_id":"79","weko_shared_id":-1},"updated":"2023-06-19T07:49:54.317511+00:00"}